|
The biotechnology industry has grown markedly in the last few years, both locally and across the United States. In Rhode Island, medical-device manufacturer Ximedica has been a key driver of that growth.
more
By Emily Greenhalgh |
|
The Center of Excellence for Explosives Detection, Mitigation and Response, one of only 12 of its kind nationally, lies quietly but actively in the heart of the University of Rhode Island’s South Kingstown campus, thanks to federal funding that next year will be up for renewal.
more
By Michael Souza |
|
Medical technology maker Covidien Plc. reported third quarter earnings of $453 million, or 93 cents per diluted share, a drop of 15.3 percent from the $535 million, or $1.07 per diluted share reported during the same period in 2011.
more
By PBN Staff
|
|
Medical technology maker Covidien Ltd. has officially opened its Shanghai-based research and development facility, the China Technology Center, the company announced Thursday.
more
By Emily Greenhalgh |
|
In a bipartisan resolution co-sponsored by R.I. Lt. Gov. Elizabeth H. Roberts, the National Lieutenant Governors Association endorsed efforts to prevent and effectively treat Alzheimer’s disease by 2025 at its annual meeting in July.
more
By Richard Asinof |
|
Medical device maker Covidience Plc. landed 510(k) clearance from the U.S. Food and Drug Administration to market its Nellcor Benside SpO2 Patient Monitoring System in the United States.
more
By Emily Greenhalgh |
|
PROVIDENCE – Performance Physical Therapy recently announced the opening of its newest of six clinics, in the Smithfield Medical Center in Smithfield. A seventh clinic is scheduled to open later this month in Barrington at 310 Maple Ave.
more
8/20/12
|
|
PROVIDENCE – Rhode Island Hospital is taking part in a multisite clinical trial to measure the efficacy of a catheter-based treatment for uncontrolled hypertension. The principal investigator is Dr. Timothy P. Murphy, interventional radiologist and director of the Vascular Disease Research Center.
more
8/20/12
|
|
WOONSOCKET – MultiCell Technologies announced on Aug. 10 its updates on preclinical research results for MCT-465 and MCT-485, the first of a family of prospective cancer therapeutics based on the use of its patented signaling technology. MCT-465 and MCT-485 are being investigated as prospective treatments for primary liver cancer and triple-negative breast cancer.
more
8/20/12
|
|
Before office workers, students and researchers can fill the former Interstate 195 land and drive development of the Knowledge District, someone will have to build a large place for them to park.
more
By Patrick Anderson |